Acalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial : Episode 4
Unmet Needs and Key Takeaways: ECHO Clinical Trial
Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
- What is your standard of care (SOC) in this patient population?
- How does this regimen (BTKi+BR) compare in efficacy and safety to your SOC?
Recent Videos
Related Content
